Humanoid, Inc. (HERB)

OTCMKTS · Delayed Price · Currency is USD
0.0300
+0.0038 (14.29%)
Aug 5, 2025, 3:03 PM EDT
14.29%
Market Cap4.71M
Revenue (ttm)21.14M
Net Income (ttm)7.02M
Shares Out157.17M
EPS (ttm)0.04
PE Ratio0.67
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200
Average Volume5,318
Open0.0250
Previous Close0.0263
Day's Range0.0250 - 0.0300
52-Week Range0.0150 - 0.1450
Beta0.64
RSI45.19
Earnings DateAug 22, 2025

About Theseus Pharmaceuticals

Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products primarily in the People’s Republic of China. It cultivates, processes, markets, and distributes various food and agro-byproducts. The company’s products include cotton, corns, barley, wheat, flax, and alfalfa; vegetables comprising onions, potatoes, beet, and peas; fruits, including apples, pears, and apricots; specialty crops c... [Read more]

Industry Farm Products
Founded 1998
Employees 245
Stock Exchange OTCMKTS
Ticker Symbol HERB
Full Company Profile

Financial Performance

In 2023, Humanoid's revenue was $21.14 million, an increase of 13.71% compared to the previous year's $18.59 million. Earnings were $7.02 million, an increase of 32.21%.

Financial Statements

News

Yasheng Group Reports Financial Results for the First Quarter of 2023:

Enters into Joint Venture to Commence Gold Mining in Arizona with Operations to Commence this Month: Awaits Final Preferred Dividend Decision of FINRA Enters into Joint Venture to Commence Gold Mining...

2 years ago - GlobeNewsWire

Rare Earth Elements Collected from Wastewater Utilizing Cyanobacteria Now Patent Pending

SAN JOSE, March 15, 2023 (GLOBE NEWSWIRE) -- SAN JOSE, CA--(March 15, 2023) - Yasheng Group, (OTC: HERB), an agricultural and biotech company with U.S. headquarters in San Jose, California today annou...

2 years ago - GlobeNewsWire

Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders

Begins Raising Capital for our Subsidiary, Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to Market Begins Raising Capital for our Subsidiary, Jove Pharmaceutics ...

2 years ago - GlobeNewsWire

Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

2 years ago - GlobeNewsWire